AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...

AstraZeneca Pharma India plans to sell its 64-acre Bengaluru facility as part of a strategic review by its parent company.

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

The boss of AstraZeneca has denied a rift with the Government after axing plans for a £450m vaccine factory in Liverpool. Sir Pascal Soriot said it was “fake news” to suggest that tension with ...

Astrazeneca has defended the £14.7 million pay package handed to chief executive Pascal Soriot, saying the group is too big ...

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.

Astrazeneca is too big and complex to base its chief executive’s pay packet on the rest of the FTSE index, according to the ...

AstraZeneca has cancelled a multi-million pound investment in a vaccine plant in Merseyside because the government failed to match the previous government's offer of support ...

AstraZeneca has pulled out of plans to build a new £450m facility in Liverpool. AstraZeneca, which produced one of the Covid-19 jabs, has an existing site on Renaissance Way, Speke and during the ...

AstraZeneca has been hit with a US class action lawsuit that claims the UK’s largest listed company misled shareholders in connection with investigations by Chinese authorities.

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...